中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌完全缓解1例报告

马菁璠 陈刚 刘洪

马菁璠, 陈刚, 刘洪. 经肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌完全缓解1例报告[J]. 临床肝胆病杂志, 2016, 32(1): 152-154. DOI: 10.3969/j.issn.1001-5256.2016.01.030
引用本文: 马菁璠, 陈刚, 刘洪. 经肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌完全缓解1例报告[J]. 临床肝胆病杂志, 2016, 32(1): 152-154. DOI: 10.3969/j.issn.1001-5256.2016.01.030
Ma JingFan, Chen Gang, Liu Hong. TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response[J]. J Clin Hepatol, 2016, 32(1): 152-154. DOI: 10.3969/j.issn.1001-5256.2016.01.030
Citation: Ma JingFan, Chen Gang, Liu Hong. TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response[J]. J Clin Hepatol, 2016, 32(1): 152-154. DOI: 10.3969/j.issn.1001-5256.2016.01.030

经肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌完全缓解1例报告

DOI: 10.3969/j.issn.1001-5256.2016.01.030
详细信息
  • 中图分类号: R735.7

TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response

  • 摘要: <正>据报道[1]每年约有750 000例肝癌新增病例,且逐年递增,其中80%85%的肝癌患者被确诊时已丧失手术机会。不能手术的患者,可采用多种局部治疗方法,其中经肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)为首选治疗方法[2-3],可取得较好的近期疗效。但它只能使肿瘤大部分坏死,早期的缺氧环境,会造成血管内皮生长因子生成增

     

  • [1]KOUDAH S,EL MOUHADI S,ARRIVL.Fibrolamellar hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol,2012,36(1):5-6.
    [2]YANG M,YUAN JQ,BAI M,et al.Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma:a systematic review and meta-analysis[J].Mol Biol Rep,2014,41(10):6575-6582.
    [3]ZHANG L,HU P,CHEN X,et al.Transarterial chemoembolization(TACE)plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma:a meta-analysis[J].PLoS One,2014,9(6):e100305.
    [4]NITTA H,BEPPU T,IMAI K,et al.Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J].World J Surg,2013,37(5):1034-1042.
    [5]KEE KM,HUNG CH,WANG JH,et al.Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib[J].Onco Targets Ther,2014,7:829-834.
    [6]IMEDIO ER,BEVERIDGE RD,URTASUN JA,et al.Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma:a single center experience[J].Med Oncol,2014,31(5):948.
    [7]GADALETA-CALDAROLA G,INFUSINO S,GALISE I,et al.Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma:a phaseⅡstudy[J].Oncol Lett,2014,8(4):1783-1787.
    [8]RICKE J,BULLA K,KOLLIGS F,et al.Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma:analysis of the European multicentre trial SORAMIC[J].Liver Int,2015,35(2):620-626.
    [9]LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
    [10]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
    [11]RONOT M,BOUATTOUR M,WASSERMANn J,et al.Alternative response criteria(Choi,European association for the study of the liver,and modified response evaluation criteria in solid tumors[RECIST])versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib[J].Oncologist,2014,19(4):394-402.
    [12]YADA M,MASUMOTO A,MOTOMURA K,et al.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma[J].World J Gastroenterol,2014,20(35):12581-12587.
    [13]ZHENG YB,ZHAN MX,ZHAO W,et al.The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib[J].Med Oncol,2014,31(10):209.
    [14]SO BJ,BEKAII-SAAB T,BLOOMSTON MA,et al.Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis:a case report[J].J Hematol Oncol,2008,1:18.
    [15]LULLA PD,BRAMMER JE,BANDEALI S,et al.Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib[J].J Gastrointest Cancer,2013,44(1):98-101.
    [16]WANG SX,BYRNES A,VERMA S,et al.Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib:a case report[J].Target Oncol,2010,5(1):59-63.
    [17]SHOMURA M,KAGAWA T,SHIRAISHI K,et al.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma[J].World J Hepatol,2014,6(9):670-676.
    [18]AKUTSU N,SASAKI S,TAKAGI H,et al.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy[J].Int J Clin Oncol,2015,20(1):105-110.
    [19]TANOGLU A,KARAGOZ E.Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib[J].Asian Pac J Cancer Prev,2014,15(2):1063.
    [20]SHAO YY,LIN ZZ,HSU C,et al.Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma[J].Cancer,2010,116(19):4590-4596.
    [21]LEE S,KIM BK,KIM SU,et al.Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy:a Korean multicenter study[J].J Gastroenterol Hepatol,2014,29(7):1463-1469.
    [22]TSUCHIYA K,ASAHINA Y,MATSUDA S,et al.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma[J].Cancer,2014,120(2):229-237.
    [23]NAGAI H,KANEKAWA T,KOBAYASHI K,et al.Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib[J].Cancer Chemother Pharmacol,2014,73(2):223-229.
  • 加载中
计量
  • 文章访问数:  1860
  • HTML全文浏览量:  11
  • PDF下载量:  380
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回